Complete Genomics
29.06.2011 14:00
---------------------------------------------------------------------------
Selected Researchers Will Receive Complete Human Genome Sequencing of Eight
Genomes
MOUNTAIN VIEW, Calif., 2011-06-29 14:00 CEST (GLOBE NEWSWIRE) --
Complete Genomics Inc. (Nasdaq:GNOM), a complete human genome sequencing
company, today announced that it is introducing a new cancer grant program.
Winning research applications will receive complete human genome sequencing of
eight genomes -- four tumor/normal pairs. Four winning entries will be chosen:
two each from the United States and Europe.
Complete Genomics is accepting grant applications for cancer-specific research
projects using its complete human genome sequencing service from now until July
29, 2011. Applications will be evaluated by an internal panel of scientific
experts at Complete Genomics. Winners will be notified by Aug. 12 and will be
required to submit their samples by Sept. 16. In addition, all applicants will
be automatically eligible for a discount on their next complete human genome
sequencing project.
'We designed this grant program to recognize and reward those scientists who
are developing innovative cancer research projects,' said Dr. Clifford Reid,
chairman, president and CEO of Complete Genomics. 'We are delighted to have the
opportunity to provide pioneering scientists with complete human genome
sequencing and research-ready data that they can immediately use to gain
insights into the characterization and possible treatment of various cancers.'
For more information about the grant program or to submit an application,
please visit at http://www.completegenomics.com/news-events/grant-program/.
About Complete Genomics
Complete Genomics is a complete human genome sequencing company that has
developed and commercialized an innovative DNA sequencing platform. The
Complete Genomics Analysis Platform (CGA(tm) Platform) combines Complete
Genomics'
proprietary human genome sequencing technology with our advanced informatics
and data management software. We offer this solution as an innovative,
end-to-end, outsourced service, CGA(tm) Service, and provide customers with data
that is immediately ready to be used for genome-based research. Additional
information can be found at http://www.completegenomics.com.
The Complete Genomics logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8216
Forward-Looking Statements
Certain statements in this press release, including statements relating to the
ability of scientists to use the genome sequencing data that we provide to them
to immediately gain insights into the characterization and possible treatment
of various cancers are forward-looking statements that are subject to risks and
uncertainties. Readers are cautioned that these forward-looking statements are
based on management's current expectations, and actual results may differ
materially from those projected. The following factors, without limitation,
could cause actual results to differ materially from those in the
forward-looking statements: the ability of scientists to successfully analyze
the genomic data we provide; and the ability of researchers to convert genomic
data into medically valuable information. More information on potential factors
that could affect the usefulness of the genomic data that we provide to our
customers is included in our Securities and Exchange Commission filings and
reports, including the risks identified under the section captioned 'Risk
Factors' in our Registration Statement on Form S-1 filed on May 18, 2011. We
disclaim any obligation to update information contained in these
forward-looking statements, whether as a result of new information, future
events or otherwise.
CONTACT: Complete Genomics Inc.
Jennifer Turcotte
Vice President of Marketing
(650) 943-2846
jturcotte@completegenomics.com
Waggener Edstrom Worldwide
Healthcare
Lisa Osborne
Account Director
(202) 261-7806
completegenomics@waggeneredstrom.com
News Source: NASDAQ OMX
29.06.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Complete Genomics
US
Phone:
Fax:
E-mail:
Internet:
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: Complete Genomics Launches Cancer Grant Program
| Quelle: EQS Group AG